Upgrading Phage Therapies to Crush Antimicrobial Resistance

Q4 Biochemistry, Genetics and Molecular Biology

Genetic Engineering & Biotechnology News Pub Date : 2023-11-01 DOI:10.1089/gen.43.11.10

Andy Tay

引用次数: 0

Abstract

Genetic Engineering & Biotechnology NewsVol. 43, No. 11 Infectious DiseaseUpgrading Phage Therapies to Crush Antimicrobial ResistanceTo speed the translation of phage therapies to the clinic, researchers are exploring delivery strategies, phage-antibiotic synergies, and genome modificationsAndy TayAndy TaySearch for more papers by this authorPublished Online:9 Nov 2023https://doi.org/10.1089/gen.43.11.10AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 43Issue 11Nov 2023 Information© 2023 by GEN PublishingTo cite this article:Andy Tay.Upgrading Phage Therapies to Crush Antimicrobial Resistance.Genetic Engineering & Biotechnology News.Nov 2023.24-26, 28, 29.http://doi.org/10.1089/gen.43.11.10Published in Volume: 43 Issue 11: November 9, 2023PDF download

查看原文本刊更多论文

升级噬菌体疗法以粉碎抗菌素耐药性

基因工程与生物技术新闻卷。升级噬菌体疗法以粉碎抗菌素耐药性为了加快噬菌体疗法向临床的转化，研究人员正在探索递送策略、噬菌体-抗生素协同作用、和基因组修改sandy TayAndy tay搜索本文作者的更多论文出版在线:2023年11月9日https://doi.org/10.1089/gen.43.11.10AboutSectionsView文章查看全文pdf /EPUB许可& citationspermissions下载CitationsTrack citations添加到收藏回到出版物ShareShare onFacebookTwitterLinked InRedditEmail查看文章figuresreferencesrelateddetails卷43发行11Nov 2023信息©2023 by GEN publishing引用本文:Andy Tay。升级噬菌体疗法以粉碎抗菌素耐药性。基因工程与生物技术新闻。2023年11月24日至26日，28日，29日。http://doi.org/10.1089/gen.43.11.10Published，第43卷第11期:2023年11月9日pdf下载

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Genetic Engineering & Biotechnology News 工程技术-生物工程与应用微生物

CiteScore

0.20

自引率

0.00%

发文量

210

审稿时长

3-6 weeks

期刊介绍： Genetic Engineering & Biotechnology News (GEN) is the flagship publication of Mary Ann Liebert, Inc. Launched in 1980, GEN was the first publication in this field and remains the key driver in the explosion of the industry, paving the way for the development of new technologies and applications, investment growth, and career opportunities. With nearly 40 years of publishing experience, GEN maintains unrivaled integrity, influence, and expertise that plays a pivotal role in driving the productivity and growth of the industry. Through its cornerstone Magazine, high-frequency newsletters, and dynamic suite of multimedia resources, GEN is the 360-degree resource that researchers and executives depend on for information that is pivotal for their organization’s success. GEN’s breadth of editorial coverage is unrivaled in the industry, providing exclusive coverage of the entire bioproduct lifecycle across five key pillars: Drug Discovery, Bioprocessing, OMICS, Translational Medicine, and Gene Editing.